Riches in Zeneca drugs pipeline; The Investment Column

Few could have guessed that shares in Zeneca would triple in the space of under four years, but since the spin-off from ICI, Britain's third-biggest drugs group has developed a reputation as one of the best on the market. The question for investors is to what extent the current price reflects long-running hopes that Roche or some other deep-pocketed rival may pounce and how much it is a measure of fundamental prospects. The former seemed to be gaining the upper hand yesterday, with the shares dipping 42p to pounds 18.605 on profit-taking and gripes that the company's new drugs pipeline was looking a little empty.

That looks churlish for a company which churned out a 15 per cent rise in underlying profits before exceptionals of pounds 1.01bn in the year to December. More so when you add in Zeneca's "aspirational target" of achieving 15 per cent a year average earnings growth over the next five years.

There was little to quibble about in last year's figures. More than 14 per cent of the underlying sales growth in the main pharmaceuticals business to pounds 2.44bn came from products launched in the past two years. The cost of developing and launching these products is holding back profits, up an underlying 6 per cent to pounds 757m in the division, but the prospects are encouraging. Casodex, the prostate cancer treatment, saw sales jump from pounds 10m to pounds 68m and now claims a 45 per cent share of the US prescriptions market. Arimidex, the breast cancer drug, managed pounds 20m sales from a standing start last year, while Accolate, Zeneca's delayed entry into the asthma market, is said to be doing better than Glaxo's rival Flovent.

The group is also excited about the prospects for Zomig, the migraine treatment acquired from Glaxo last year. News that Zomig has won its first official approval, from the UK, will pit it against Glaxo's rival Naramig product, which has also just gained its first clearance, from Sweden.

But this is a big market and both Zomig and the Seroquel schizophrenia drug to be launched later this year are set to achieve peak sales well in excess of pounds 200m.

These and other launches should tide the group over any temporary gap in drugs in late-stage trials, while further out, some of the 18 products in the development pipeline will come good. The company can also use its pounds 272m net cash to plug any holes: Zestril, the group's best-selling heart drug, was after all acquired from Merck.

Currency could hit this year's figures, so profits of pounds 1.1bn would put the shares on a heady forward multiple of 24, but by 1998 that could have fallen to 20, in line with SmithKline Beecham and Glaxo. Hold on.

Start your day with The Independent, sign up for daily news emails
PROMOTED VIDEO
Life and Style
Suited and booted in the Lanvin show at the Paris menswear collections
fashionParis Fashion Week
Arts and Entertainment
Kara Tointon and Jeremy Piven star in Mr Selfridge
tvActress Kara Tointon on what to expect from Series 3
Voices
Winston Churchill, then prime minister, outside No 10 in June 1943
voicesA C Benson called him 'a horrid little fellow', George Orwell would have shot him, but what a giant he seems now, says DJ Taylor
News
i100
News
An asteroid is set to pass so close to Earth it will be visible with binoculars
news
Arts and Entertainment
Benedict Cumberbatch has spoken about the lack of opportunities for black British actors in the UK
film
News
ebooks
ebooksA year of political gossip, levity and intrigue from the sharpest pen in Westminster
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Tax Assistant

Negotiable: Recruitment Genius: A Tax Assistant is required to join a leading ...

Recruitment Genius: Outbound Sales Executive - OTE £25,000

£16000 - £25000 per annum: Recruitment Genius: This is an exciting opportunity...

Ashdown Group: Java Developer / J2EE Developer - Watford - £45,000 - £47,000

£45000 - £47000 per annum + bonus + benefits: Ashdown Group: Java Developer / ...

Ashdown Group: Marketing Product Manager - (Financial Services) - SW London

£35000 - £38000 per annum + Benefits: Ashdown Group: Marketing Manager - Marke...

Day In a Page

Syria crisis: Celebrities call on David Cameron to take more refugees as one young mother tells of torture by Assad regime

Celebrities call on David Cameron to take more Syrian refugees

One young mother tells of torture by Assad regime
The enemy within: People who hear voices in their heads are being encouraged to talk back – with promising results

The enemy within

People who hear voices in their heads are being encouraged to talk back
'In Auschwitz you got used to anything'

'In Auschwitz you got used to anything'

Survivors of the Nazi concentration camp remember its horror, 70 years on
Autumn/winter menswear 2015: The uniforms that make up modern life come to the fore

Autumn/winter menswear 2015

The uniforms that make up modern life come to the fore
'I'm gay, and plan to fight military homophobia'

'I'm gay, and plan to fight military homophobia'

Army general planning to come out
Iraq invasion 2003: The bloody warnings six wise men gave to Tony Blair as he prepared to launch poorly planned campaign

What the six wise men told Tony Blair

Months before the invasion of Iraq in 2003, experts sought to warn the PM about his plans. Here, four of them recall that day
25 years of The Independent on Sunday: The stories, the writers and the changes over the last quarter of a century

25 years of The Independent on Sunday

The stories, the writers and the changes over the last quarter of a century
Homeless Veterans appeal: 'Really caring is a dangerous emotion in this kind of work'

Homeless Veterans appeal

As head of The Soldiers' Charity, Martin Rutledge has to temper compassion with realism. He tells Chris Green how his Army career prepared him
Wu-Tang Clan and The Sexual Objects offer fans a chance to own the only copies of their latest albums

Smash hit go under the hammer

It's nice to pick up a new record once in a while, but the purchasers of two latest releases can go a step further - by buying the only copy
Geeks who rocked the world: Documentary looks back at origins of the computer-games industry

The geeks who rocked the world

A new documentary looks back at origins of the computer-games industry
Belle & Sebastian interview: Stuart Murdoch reveals how the band is taking a new direction

Belle & Sebastian is taking a new direction

Twenty years ago, Belle & Sebastian was a fey indie band from Glasgow. It still is – except today, as prime mover Stuart Murdoch admits, it has a global cult following, from Hollywood to South Korea
America: Land of the free, home of the political dynasty

America: Land of the free, home of the political dynasty

These days in the US things are pretty much stuck where they are, both in politics and society at large, says Rupert Cornwell
A graphic history of US civil rights – in comic book form

A graphic history of US civil rights – in comic book form

A veteran of the Fifties campaigns is inspiring a new generation of activists
Winston Churchill: the enigma of a British hero

Winston Churchill: the enigma of a British hero

A C Benson called him 'a horrid little fellow', George Orwell would have shot him, but what a giant he seems now, says DJ Taylor
Growing mussels: Precious freshwater shellfish are thriving in a unique green project

Growing mussels

Precious freshwater shellfish are thriving in a unique green project